Non Alcoholic Fatty Liver Disease-Pipeline Review H2 2017
ReportsWeb.com has announced the addition of the “Non Alcoholic Fatty Liver Disease-Pipeline Review H2 2017” this report provides an overview of the Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline landscape.
(EMAILWIRE.COM, July 26, 2017 ) Nonalcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease. Nonalcoholic fatty liver disease is common and for most people causes no signs and symptoms and no complications. But in some people with nonalcoholic fatty liver disease the fat that accumulates can cause inflammation and scarring in the liver. The most common symptoms that bring NAFLD to medical attention are malaise fatigue and right upper quadrant or diffuse abdominal discomfort.
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline Review H2 2017 provides comprehensive information on the therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) complete with analysis by stage of development drug target mechanism of action (MoA) route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics its complete research and development history and latest news and press releases.
The Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Non Alcoholic Fatty Liver Disease (NAFLD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes the molecules developed by Companies in Phase III Phase II Phase I Preclinical Discovery and Unknown stages are 2 15 11 22 5 and 1 respectively. Similarly the Universities portfolio in Preclinical stages comprises 2 molecules respectively.
Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases company/university websites clinical trial registries conferences SEC filings investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
For more information about this report at http://www.reportsweb.com/non-alcoholic-fatty-liver-disease-pipeline-review-h2-2017
Report Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) .
- The pipeline guide reviews pipeline therapeutics for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise product description descriptive licensing and collaboration details R&D brief MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) therapeutics based on mechanism of action (MoA) drug target route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal)
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001881455/sample
Reasons to buy
- Procure strategically important competitor information analysis and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) .
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Company profiles
Akcea Therapeutics Inc
Allergan Plc
Ardelyx Inc
AstraZeneca Plc
Betagenon AB
Bird Rock Bio Inc
Boehringer Ingelheim GmbH
Can-Fite BioPharma Ltd
Cerenis Therapeutics Holding SA
CJ HealthCare Corp
Conatus Pharmaceuticals Inc
Corcept Therapeutics Inc
CymaBay Therapeutics Inc
Daewoong Pharmaceutical Co Ltd
Dimerix Bioscience Pty Ltd
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001881455/discount
List of Tables
Number of Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD) H2 2017
Number of Products under Development by Companies H2 2017
Number of Products under Development by Companies H2 2017 (Contd..1) H2 2017
Number of Products under Development by Companies H2 2017 (Contd..2) H2 2017
Number of Products under Development by Universities/Institutes H2 2017
Products under Development by Companies H2 2017
Products under Development by Companies H2 2017 (Contd..1) H2 2017
Products under Development by Companies H2 2017 (Contd..2) H2 2017
Products under Development by Universities/Institutes H2 2017
Number of Products by Stage and Target H2 2017
Number of Products by Stage and Target H2 2017 (Contd..1) H2 2017
Number of Products by Stage and Target H2 2017 (Contd..2) H2 2017
Number of Products by Stage and Mechanism of Action H2 2017
Number of Products by Stage and Mechanism of Action H2 2017 (Contd..1) H2 2017
Number of Products by Stage and Mechanism of Action H2 2017 (Contd..2) H2 2017
Number of Products by Stage and Route of Administration H2 2017
Number of Products by Stage and Molecule Type H2 2017
Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline by Akcea Therapeutics Inc H2 2017
Purchase Complete Report at http://www.reportsweb.com/buy&RW0001881455/buy/2000
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline Review H2 2017 provides comprehensive information on the therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) complete with analysis by stage of development drug target mechanism of action (MoA) route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics its complete research and development history and latest news and press releases.
The Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Non Alcoholic Fatty Liver Disease (NAFLD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes the molecules developed by Companies in Phase III Phase II Phase I Preclinical Discovery and Unknown stages are 2 15 11 22 5 and 1 respectively. Similarly the Universities portfolio in Preclinical stages comprises 2 molecules respectively.
Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases company/university websites clinical trial registries conferences SEC filings investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
For more information about this report at http://www.reportsweb.com/non-alcoholic-fatty-liver-disease-pipeline-review-h2-2017
Report Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) .
- The pipeline guide reviews pipeline therapeutics for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise product description descriptive licensing and collaboration details R&D brief MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) therapeutics based on mechanism of action (MoA) drug target route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal)
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001881455/sample
Reasons to buy
- Procure strategically important competitor information analysis and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) .
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Company profiles
Akcea Therapeutics Inc
Allergan Plc
Ardelyx Inc
AstraZeneca Plc
Betagenon AB
Bird Rock Bio Inc
Boehringer Ingelheim GmbH
Can-Fite BioPharma Ltd
Cerenis Therapeutics Holding SA
CJ HealthCare Corp
Conatus Pharmaceuticals Inc
Corcept Therapeutics Inc
CymaBay Therapeutics Inc
Daewoong Pharmaceutical Co Ltd
Dimerix Bioscience Pty Ltd
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001881455/discount
List of Tables
Number of Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD) H2 2017
Number of Products under Development by Companies H2 2017
Number of Products under Development by Companies H2 2017 (Contd..1) H2 2017
Number of Products under Development by Companies H2 2017 (Contd..2) H2 2017
Number of Products under Development by Universities/Institutes H2 2017
Products under Development by Companies H2 2017
Products under Development by Companies H2 2017 (Contd..1) H2 2017
Products under Development by Companies H2 2017 (Contd..2) H2 2017
Products under Development by Universities/Institutes H2 2017
Number of Products by Stage and Target H2 2017
Number of Products by Stage and Target H2 2017 (Contd..1) H2 2017
Number of Products by Stage and Target H2 2017 (Contd..2) H2 2017
Number of Products by Stage and Mechanism of Action H2 2017
Number of Products by Stage and Mechanism of Action H2 2017 (Contd..1) H2 2017
Number of Products by Stage and Mechanism of Action H2 2017 (Contd..2) H2 2017
Number of Products by Stage and Route of Administration H2 2017
Number of Products by Stage and Molecule Type H2 2017
Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline by Akcea Therapeutics Inc H2 2017
Purchase Complete Report at http://www.reportsweb.com/buy&RW0001881455/buy/2000
Contact Information:
ReportsWeb.com
Rajat Sahni
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
ReportsWeb.com
Rajat Sahni
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results